Details for Patent: 8,450,372

✉ Email this page to a colleague

Which drugs does patent 8,450,372 protect, and when does it expire?

Patent 8,450,372 protects ZOLINZA and is included in one NDA.

This patent has forty-one patent family members in twenty-three countries.

Summary for Patent: 8,450,372

Patent landscape, scope, and claims:

Title:	Formulations of suberoylanilide hydroxamic acid and methods for producing same
Abstract:	The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline composition or pharmaceutical composition. The present invention also provides compositions with a specific particle size distribution.
Inventor(s):	Wong; Jeannie Chow (Chicago, IL), Cote; Aaron S. (West Windsor, NJ), Dienemann; Erik A. (Metuchen, NJ), Gallagher; Kimberly (Green Lane, PA), Ikeda; Craig (Harleysville, PA), Moser; Justin (Collegeville, PA), Rajniak; Pavol (Lansdale, PA), Reed; Robert A. (Line Lexington, PA), Starbuck; Cindy (Branchburg, NJ), Tung; Hsien-Hsin (Edison, NJ), Wang; Qingxi (Ambler, PA), Cohen; Benjamin Max (Cranford, NJ), Capodanno; Vincent R. (Hillsborough, NJ), Sell; Brian (Royersford, PA), Miller; Thomas A. (Wakefield, MA)
Assignee:	Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:	12/686,843
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form; Process;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 8,450,372

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Msd Sub Merck	ZOLINZA	vorinostat	CAPSULE;ORAL	021991-001	Oct 6, 2006		RX	Yes	Yes	8,450,372	⤷ Subscribe				TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,450,372

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	055953	⤷ Subscribe
Argentina	095159	⤷ Subscribe
Australia	2006249440	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.